BCR and mantle cell lymphoma: This is in agreement with our results with pharmacological inhibitors: the specific PI3Kδ inhibitor idelalisib did not inhibit BCR-controlled adhesion in Namalwa, in contrast to the inhibition observed in the MCL cell line JeKo-1, but the pan-PI3K inhibitor wortmannin did inhibit adhesion (Supplementary Fig. 3).